Oakbrook Investments LLC Cuts Position in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)

Oakbrook Investments LLC lessened its position in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 13.1% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 10,625 shares of the biopharmaceutical company’s stock after selling 1,600 shares during the quarter. Oakbrook Investments LLC’s holdings in Alexion Pharmaceuticals were worth $1,041,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ALXN. Steward Partners Investment Advisory LLC purchased a new position in Alexion Pharmaceuticals during the 2nd quarter valued at approximately $28,000. Redhawk Wealth Advisors Inc. purchased a new position in Alexion Pharmaceuticals during the 2nd quarter valued at approximately $29,000. Ossiam purchased a new position in Alexion Pharmaceuticals during the 2nd quarter valued at approximately $32,000. Capital Bank & Trust Co grew its holdings in Alexion Pharmaceuticals by 355.9% during the 2nd quarter. Capital Bank & Trust Co now owns 269 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 210 shares in the last quarter. Finally, NEXT Financial Group Inc purchased a new position in Alexion Pharmaceuticals during the 2nd quarter valued at approximately $36,000. Institutional investors and hedge funds own 93.26% of the company’s stock.

ALXN opened at $98.41 on Monday. The business has a fifty day moving average of $101.88 and a 200 day moving average of $118.85. Alexion Pharmaceuticals, Inc. has a 52-week low of $92.56 and a 52-week high of $141.86. The company has a quick ratio of 3.56, a current ratio of 4.04 and a debt-to-equity ratio of 0.26. The stock has a market cap of $22.42 billion, a P/E ratio of 13.88, a PEG ratio of 0.95 and a beta of 1.67.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings data on Wednesday, July 24th. The biopharmaceutical company reported $2.64 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.13 by $0.51. Alexion Pharmaceuticals had a return on equity of 20.23% and a net margin of 29.64%. The company had revenue of $1.20 billion during the quarter, compared to analysts’ expectations of $1.18 billion. During the same quarter in the previous year, the business earned $2.07 EPS. Alexion Pharmaceuticals’s revenue was up 15.1% compared to the same quarter last year. Equities analysts anticipate that Alexion Pharmaceuticals, Inc. will post 9.06 EPS for the current fiscal year.

Several equities analysts have weighed in on ALXN shares. Citigroup set a $150.00 price target on Alexion Pharmaceuticals and gave the company a “buy” rating in a report on Friday, August 30th. Leerink Swann set a $157.00 price target on Alexion Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, September 3rd. Piper Jaffray Companies set a $180.00 price target on Alexion Pharmaceuticals and gave the company a “buy” rating in a report on Friday, September 6th. Stifel Nicolaus restated a “hold” rating on shares of Alexion Pharmaceuticals in a report on Friday, August 30th. Finally, Bank of America initiated coverage on Alexion Pharmaceuticals in a report on Thursday. They issued a “buy” rating for the company. One analyst has rated the stock with a sell rating, five have issued a hold rating and fifteen have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $159.76.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

Read More: Leveraged Buyout (LBO)

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.